WO2009100605A1 - 一种治疗消渴病的药物组合物及其制备方法 - Google Patents
一种治疗消渴病的药物组合物及其制备方法 Download PDFInfo
- Publication number
- WO2009100605A1 WO2009100605A1 PCT/CN2008/001878 CN2008001878W WO2009100605A1 WO 2009100605 A1 WO2009100605 A1 WO 2009100605A1 CN 2008001878 W CN2008001878 W CN 2008001878W WO 2009100605 A1 WO2009100605 A1 WO 2009100605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- volume
- solution
- pharmaceutical composition
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the invention relates to a pharmaceutical composition and a preparation method thereof, in particular to a pharmaceutical composition for treating diabetes, a preparation method thereof and a quality control method.
- diabetes diabetes
- diabetes diabetes
- the efficacy of traditional Chinese medicine hypoglycemic drugs is not satisfactory, and the drugs commonly used in the treatment of diabetes, such as Bai Tangping, can cause flatulence and bowel Such side effects, therefore, it is necessary to carry out research on prevention and treatment of diabetes.
- One object of the present invention is to disclose a pharmaceutical composition for treating diabetes, and another object of the present invention is to disclose a method for preparing the pharmaceutical composition and a method for controlling the quality thereof.
- the object of the present invention is achieved by the following technical solutions:
- the raw material composition of the pharmaceutical composition of the present invention is:
- the raw material composition of the pharmaceutical composition of the present invention is preferably:
- the raw material composition of the pharmaceutical composition of the present invention is preferably:
- the raw material composition of the pharmaceutical composition of the present invention is preferably:
- the pharmaceutical composition of the present invention is added into a conventional auxiliary material, and is prepared into a tablet, a capsule, a powder, a soft gelatin, a dropping pill, a honey pill, a pill, a granule, a honey refining ointment, a sustained release preparation, and an immediate release according to a conventional process.
- the preparation method of the pharmaceutical composition of the present invention may further comprise: Take silkworm sand, add 2-6 times the amount of silkworm, 50%-70% ethanol, immerse overnight, slowly heat to boiling, reflux 1-3 times, each time 0. 5- 1. 5 hours, filtered, combined filtrate , Ethanol recovery >
- the filtrate after removing the ethanol is heated and concentrated or concentrated under reduced pressure at a temperature of 80 ° C or less to a relative density of 0.95 - 1. 1 0 (measured at a temperature of 55 ° C) to obtain a concentrate, and to add water.
- the temperature is maintained at 55 ° C.
- the temperature is measured at a temperature of 55 ° C.
- the temperature is maintained at a temperature of 55 ° C.
- the temperature is maintained at a temperature of 55 ° C.
- Thick paste A, spare take licorice, decocted with licorice 8-15 times water for 1-3 times, each time 1-3 hours, combine the decoction, place overnight to precipitate, concentrate the supernatant B to
- the relative density is 1. 00-1. 15 (measured at a temperature of 55 ° C) thick paste B, spare; combined thick paste A and thick paste B, according to conventional methods, add conventional excipients to make tablets, capsules, powder , soft gelatin, dropping pills, honey pills, pills, granules, honey refining paste, sustained release preparation, immediate release preparation, controlled release preparation, oral liquid preparation or injection preparation.
- the filtrate is recovered, and the filtrate is removed by heating or concentrated under reduced pressure at a temperature of 80 ° C or lower to a relative density of 0.91 - 1. 1 0 (measured at a temperature of 55 ° C) to obtain a concentrate,
- the water is heated to a temperature of 55 ° C.
- the temperature is maintained at a temperature of 55 ° C.
- the temperature is maintained at a temperature of 55 ° C.
- the temperature is maintained at a temperature of 80 ° C.
- Test thick paste A, spare; take licorice, decocted with licorice 8-15 times water for 1-3 times, each time 1-3 hours, combine the decoction, set overnight to precipitate, take the supernatant B concentrated To a relative density of 1. 00-1.
- the preparation method of the pharmaceutical composition of the present invention is preferably:
- the quality control method of the pharmaceutical composition of the present invention comprises one or more of the following identification and/or content determinations:
- the monoammonium salt containing glycyrrhizic acid is 0. 0001-0. 0003g, and the glycyrrhizic acid is 0. 00019-0. 00020g.
- the solution of the present invention Take the pharmaceutical composition of the present invention 1. 0- 3. 0g, placed in a 25ml volumetric flask, add the above mobile phase 18-22ml, ultrasonic treatment for 20-40 minutes at a power of 250W, frequency 50KHz, take out, let cool 005-0. 015ml , injected into the liquid phase, the mobile phase is added to the mark, shaken, centrifuged, and the supernatant is taken to prepare a test solution; The test sample should present the same color peak as the reference retention time.
- the quality control method of the pharmaceutical composition of the present invention is preferably one or more of the following identification and/or content determinations:
- A taking the pharmaceutical composition of the present invention 0. 5g, adding anhydrous ethanol 5ml, 60 ° C water bath reflux for 30 minutes, placed, take the supernatant, steamed to lml in a water bath, as a test solution; 002ml, respectively, on the same silica gel, the solution was taken as a reference solution, and the solution was used as a reference solution.
- 0002g, equivalent glycyrrhizic acid is 0. 0001959g, made into a reference solution; take 2g of the pharmaceutical composition of the invention, placed in a 25ml volumetric flask, add the above mobile phase 20ml, Power 250W, frequency 50KHz for ultrasonic treatment for 30 minutes, take out, let cool, add mobile phase to the scale, shake the hook, centrifuge, take the supernatant, make the test solution; accurately draw the reference solution and the test solution Each 0. 01ml was injected into the liquid chromatograph, and the test sample should exhibit the same peak as the retention time of the control.
- 0 phosphate buffer is divided into 3, 3 ml of sodium bicarbonate solution, in a water bath at 60 ° C for 1 hour, taken out, cooled, transferred to a 10 ml volumetric flask, with 0.2 mol / L, pH 7.0 phosphate buffer 3 005ml ⁇ 0.
- the parts by weight and parts by volume of the present invention are in grams per milliliter.
- the quality control method of the pharmaceutical composition of the present invention can be applied to various dosage forms of the composition, such as tablets, capsules, powders, soft gelatinizers, dropping pills, honey pills, pills, granules, honey refining pastes, sustained release.
- a clinically acceptable dosage form such as a preparation, an immediate release preparation, a controlled release preparation, an oral liquid preparation or an injection preparation, and since the preparations of the different dosage forms contain the same amount of the crude drug, the dosage forms are controlled by the respective dosage forms.
- the sample size can be uniformly converted into a considerable amount of crude drug.
- the quality control method is equivalent to 65 g (daily dose) per unit preparation, and each unit preparation can also be used for each tablet, each tablet, each tube or each pill. .
- Fig.3 Effect of MC on blood glucose curve after sucrose loading in mice with alloxan hyperglycemia
- Fig.4 Effect of MC on blood glucose curve after starch loading in mice with alloxan hyperglycemiaFig.5 Blood glucose curve after MC experiment on health volunteers Impact
- the pharmaceutical composition of the invention has better effect than the single drug substance alone, and the combination of the two drugs has a synergistic effect, and in addition to the hypoglycemic effect, there is still an effect of improving intestinal flatulence.
- the general condition of eating more polydipsia in rats with hyperoxe hyperglycemia can be obviously improved; blood sugar and serum fructosamine can be significantly decreased; serum cholesterol content is significantly decreased, serum glycerin Triester levels have also decreased; serum NAG enzyme activity has decreased significantly, It shows that it can improve the microvascular complications; significantly reduce the sorbitol content in the sciatic nerve, suggesting an improvement of chronic neuropathy in diabetes; increasing the GSH content of red blood cells, enhancing the body's antioxidant capacity; and significantly reducing kidney weight and body mass index.
- the pharmaceutical composition of the present invention has stronger activity for inhibiting ⁇ -glucosidase in vitro, but has no inhibitory effect on ⁇ -amylase, indicating the present invention
- the pharmaceutical composition can reduce the increase of blood glucose caused by the hydrolysis of the disaccharide into the blood, and the incidence of gastrointestinal side effects is lower than that of the similar products.
- test examples 1-8 used the following test drugs and experimental animals:
- Test drug 1.
- the pharmaceutical composition extract powder of the present invention prepared by using the first embodiment, referred to as MC, provided by the Institute of Materia Medica, Chinese Academy of Medical Sciences, batch number: 96102, equivalent to 16.7 g of crude drug per gram of extract powder; Dissolve MC extract powder; 2.
- Acarbose Produced by Bayer Pharmaceuticals, Germany, batch number 264086D o
- mice Kunming mice, Jingdong Guanzizi (1994) No. 029; wi s tar rats, Jingdong Guanzizi (1994) No. 030, all purchased from the Institute of Zoology, Chinese Academy of Medical Sciences, small Rat 22-25g, rat 180-250g, sex: male, number of animals per group: 10 animals.
- Alloxan hyperglycemia mouse, rat model normal animals were injected with alloxan (mouse 90-100 mg/kg, rat 45-50 mg/kg), and blood glucose was predicted after 72 hours of administration (glucose oxidation) Enzymatic method, the experiment was carried out using a blood glucose level of 11.1 inmo l /L or more.
- mice 5 groups, 10 rats in each group, fasted overnight before the experiment, a group of 4.0 g / kg oral sucrose solution as a control group, a group of oral sucrose and Bai Tang Ping Acarbose 10 rag / kg as a positive control
- the other three groups were given sucrose and different doses of MC0. 45 g/kg, 0.9 g/kg, 1. 8 g/kg; 0 min and 30 min, 60 min, 120 min after dosing.
- Blood sugar levels see Figure 1, Table 1: Table 1. Effect of MC on blood glucose peak, peak time and curve area after sucrose loading in normal mice
- AUC is the area under the blood glucose curve; compared with the control group * ⁇ 0. 05, ** ⁇ 0. 01, *** ⁇ 0. 001 ; MC dose is g/kg.
- MC can reduce the area under the blood glucose curve after oral administration of sucrose in normal mice, so that the peak value of blood glucose is significantly decreased and moved backwards, which is basically consistent with the effect of Baitangping, and has a dose-effect relationship.
- mice 50 normal mice were divided into 5 groups and fasted overnight.
- One group was treated with soluble starch 3.0 g/kg as a control group, and one group of oral starch was compared with Baitangping 10 mg/kg as a positive drug.
- the other three groups were treated with oral starch and different doses of MC (0.55 g/kg, 0.9 g/kg, 1. 8 g/kg) for 0 min and 30 min, 60 min, 120 min after dosing.
- Table 2 The blood sugar level, the results are shown in Figure 2, Table 2:
- AUC is the area under the blood glucose curve; compared with the control group ** P ⁇ 0.01, * ** p ⁇ 0. 001; MC dose is g/kg.
- AUC is the area under the blood glucose curve; MC dose is g/kg.
- AUC is the area under the blood glucose curve; compared with the control group * P ⁇ 0.05, ** P ⁇ 0.01, *** p ⁇ 0.001; MC dose is g / kg.
- mice Groups of alloxan hyperglycemia mice, 10 rats in each group, fasted overnight, one group was fed with starch (3.0 g/kg) as a control group, and one group was given starch and Baitangping (10 mg/kg). The other groups were given starch and different doses of C (0.6 g/kg, 1.2 g/kg, 1.8 g/kg), and the blood glucose levels of Omin and 30 min, 60 min, 120 min after administration were measured, as shown in Fig. 4. 5.
- AUC is the area under the blood glucose curve; compared with the control group * P ⁇ 0.05, ** P ⁇ 0.01, *** p ⁇ 0.001; MC dose is g / kg.
- AUC (mmol/L. hr) 12.2 ⁇ 1.9 8.8 ⁇ 0.5* 11.5 ⁇ 3.1 10.0 ⁇ 1.2
- AUC is the area under the blood glucose curve; before and after comparison * P ⁇ 0. 05, * P * 0. 05
- Preliminary results indicate that MC can reduce the peak blood glucose level after normal taro test, and reduce the area under the blood glucose curve, so that the peak shifts And in a dose-effect relationship.
- Hyperglycemic animals are often accompanied by hyperlipidemia, and lowering blood sugar can improve hyperlipidemia.
- the blood lipid was determined by the enzyme method, and the kit was purchased from Beijing Zhongsheng Bioengineering High Technology Company.
- NAG enzyme is a lysosomal enzyme widely present in the renal parenchyma. It is closely related to the level of urinary albumin and the degree of retinal microangiopathy, and is a sensitive indicator of microvascular disease. As microvascular disease worsens, NAG enzyme activity increases.
- the sorbitol pathway is closely related to the occurrence and development of chronic complications of diabetes.
- the degree of increase in sorbitol content in the tissue directly reflects the degree of activity of the sorbitol pathway metabolism.
- the sodium arsenite-chromic acid method was used for the determination.
- Free radical theory is one of the important theories to explain the occurrence and development of certain chronic complications of diabetes from the level of molecular biology.
- the GSH of red blood cells is often at a low level. Therefore, measuring GSH in tissue cells can understand the strength of the body against free radical damage.
- the ⁇ value is compared with the hyperglycemia rat group; the MC dose is g/kg
- Determination of blood urea nitrogen and creatinine levels can be predicted changes in renal function.
- An increase in serum urea nitrogen and creatinine indicates abnormal renal function.
- the rats in each group were fixed with 10% formalin, routinely sectioned, stained with hematoxylin and eosin, and observed under light microscope.
- the normal rat kidney structure was normal (see Figure 8), no lesions were found; in the hyperglycemia group, the renal ductal epithelial cells in some kidneys were vacuolated, and the intracellular glycogen was dissolved during the preparation process.
- the cell membrane was clearly visible (see Figure 9); no changes were seen in the renal tubules of the MC group (see Figure 10).
- the glycopathic 'pathology is caused by increased blood sugar through the small ball and then absorbed by the renal tubular epithelial cells. After the blood sugar and urine sugar are reduced, the lesion can be alleviated.
- MC also improves the renal artery lesions while lowering blood sugar and urine sugar.
- test sample the pharmaceutical composition of the present invention prepared in Example 1, abbreviated as MC;
- Positive control drugs Acarbose, Orlister (Or l i s ta t ).
- mice normal Wi s tar rats, 250-300 g, used to extract intestinal mucosa ⁇ -grape Glycosidase.
- triolein As a substrate, Orlistat as a positive control drug, MC of the test sample reacted with porcine pancreatic lipase and lipoprotein adipose, respectively, and oleic acid was released from triolein. The dry rate was used to determine the inhibitory activity of the sample on lipase. The results are shown in Table 15:
- Orlistat 10 100% 100% The results show that MC has little inhibitory effect on lipase.
- the experimental results showed that the sample MC had a strong inhibitory effect on ⁇ -sucrose and maltase activities, and the inhibition IC50 was 2.53 /1111 and 4.05 ⁇ g/ml, respectively; there was no inhibition on ⁇ -amylase. It is indicated that MC inhibits only the disaccharide hydrolase without inhibiting the activity of ⁇ -amylase, and greatly reduces the amount of incompletely hydrolyzed starch and oligosaccharides entering the lower end of the small intestine, and only a part of the residual disaccharide enters the lower end of the small intestine. Reduce the blood sugar rise caused by the hydrolysis of disaccharide into the blood High, the incidence of gastrointestinal side effects is lower than that of Bai Tangping. MC has no inhibitory effect on lipase, indicating that MC can not directly affect the absorption of fat from the intestine.
- Example 6 Preparation of oral liquid preparation Silkworm sand 6. 15kg licorice 0. 1875kg
- Example 8 Method for determining content of pharmaceutical composition capsule of the present invention and method for identifying same
- 0 phosphate buffer is divided into 3 washing containers, the washing liquid is incorporated into the measuring bottle, and the above-mentioned solution of the solution is diluted to the mark, and the hook is made to prepare a reference solution;
- the prepared pharmaceutical composition capsule of the present invention has a content of 0.4 g, placed in a 10 ml stoppered test tube, and added with water 5 ml. After fully shaking, it is heated in a water bath at 60 ° C for 30 minutes, taken out, allowed to cool, and transferred to a volume of 10 ml.
- the pharmaceutical composition of the present invention is dosed daily 0018g o
- Example 9 Method for identifying powder of pharmaceutical composition of the present invention
- the solution of the pharmaceutical composition of the present invention is 0. 4g, adding anhydrous ethanol 6ml, 40 ° C water bath reflux 4G minutes, placed, the supernatant is taken, placed in a water bath steamed to 0. 5ml, as a test solution; 001ml, respectively, the same silica gel was taken as the reference substance, and the solution was added to the same silica gel as the reference solution.
- Example 10 Method for determining the content of granules of pharmaceutical composition of the present invention
- 0.5 trichloromethane acetone as a developing agent, unroll, take out, dry, spray with 10% phosphomolybdic acid solution, Heating at 105 °C until the spot color is clear; in the chromatogram of the test sample, the spot of the same color is displayed at the position corresponding to the color term of the reference product;
- Chromatographic conditions and system suitability test octadecylsilane bonded silica as a filler; 21:0. 5: 79 acetonitrile-dimercaptocarboxamide 0. 025mol / L sodium acetate solution
- the mobile phase; the detection wavelength is 390nm; the number of theoretical plates should be no less than 2500 according to the peak of the picolinic acid; accurately weigh the reference product of the cockrole acid 0. 005g, placed in a 50ml volumetric flask, dilute to the mark with water, shake Exactly take 1ml, set 10ml plugged test tube, add water lml, add 0.
- 15 thick paste A, spare take licorice, decocted with licorice 10 times the amount of water, 2 times, 2 hours each time, the decoction is combined, placed overnight to precipitate, and the supernatant B is concentrated to a temperature of 55 ° C, a relative density of 1. 04-1.
- 15 thick paste B, spare combined thick paste A and thick paste B, a conventional excipient is added, and a tablet is prepared in a conventional manner.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Insects & Arthropods (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1009713.7A GB2469220B (en) | 2008-01-30 | 2008-11-14 | Pharmaceutical composition for treating diabetes and preparation method thereof |
CA2710862A CA2710862C (en) | 2008-01-30 | 2008-11-14 | Pharmaceutical composition for treating diabetes and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100571303A CN101496829B (zh) | 2008-01-30 | 2008-01-30 | 一种治疗消渴病的药物组合物及其制备方法 |
CN200810057130.3 | 2008-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009100605A1 true WO2009100605A1 (zh) | 2009-08-20 |
Family
ID=40944238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/001878 WO2009100605A1 (zh) | 2008-01-30 | 2008-11-14 | 一种治疗消渴病的药物组合物及其制备方法 |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN101496829B (zh) |
CA (1) | CA2710862C (zh) |
GB (1) | GB2469220B (zh) |
WO (1) | WO2009100605A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114594178A (zh) * | 2022-01-25 | 2022-06-07 | 贵州健安德科技有限公司 | 一种利用hplc检测30%氯虫苯甲酰胺悬浮剂中3-甲基吡啶的方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104095178A (zh) * | 2013-04-09 | 2014-10-15 | 北京宏泰康达医药科技有限公司 | 一种辅助降血糖的组合物 |
CN103536649B (zh) * | 2013-10-17 | 2015-05-20 | 漳州片仔癀药业股份有限公司 | 一种金糖宁胶囊的制备方法 |
CN104007206B (zh) * | 2014-06-13 | 2015-05-27 | 漳州片仔癀药业股份有限公司 | 一种蚕沙药材的检测方法 |
CN104007205B (zh) * | 2014-06-13 | 2015-09-30 | 漳州片仔癀药业股份有限公司 | 一种治疗消渴病的药物制剂的检测方法 |
CN105004829B (zh) * | 2015-07-21 | 2017-06-16 | 漳州片仔癀药业股份有限公司 | 一种金糖宁胶囊的质量检测方法 |
CN109007145A (zh) * | 2018-07-26 | 2018-12-18 | 佛山科学技术学院 | 一种多效保健红茶饮料的制备方法 |
CN110279719B (zh) * | 2019-06-27 | 2021-01-15 | 北京市房山区中医医院 | 治疗糖尿病胃轻瘫的晚蚕沙外熨包及其制备和使用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1277027A (zh) * | 1999-06-14 | 2000-12-20 | 中国医学科学院药物研究所 | 蚕沙提取方法、提取物及其用途 |
KR20030079237A (ko) * | 2002-04-02 | 2003-10-10 | 최진호 | 누에 추출물을 이용한 항당뇨환자식의 조성물 |
CN1557824A (zh) * | 2004-02-13 | 2004-12-29 | 南开大学 | 蚕沙总生物碱及其制备方法 |
CN1559539A (zh) * | 2004-02-23 | 2005-01-05 | 南开大学 | 具有α-糖苷酶抑制活性的药物组合物及其用途 |
CN1817350A (zh) * | 2005-12-09 | 2006-08-16 | 南开大学 | 一种蚕沙总生物碱及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908628A (en) * | 1998-05-01 | 1999-06-01 | Hou; Liping | Compositions with analgesic, antipyretic and antiinflammatory properties |
US6350476B1 (en) * | 2000-05-22 | 2002-02-26 | Shanxi Zhengzhon Pharmaceutical Co., Ltd. | Herbal chinese joint complex |
WO2005074963A1 (en) * | 2004-02-06 | 2005-08-18 | Korea Institute Of Oriental Medicine | Composition for prevention and treatment of diabetic complication |
CN100425268C (zh) * | 2005-11-15 | 2008-10-15 | 李乃荣 | 一种治疗痛风的药物 |
-
2008
- 2008-01-30 CN CN2008100571303A patent/CN101496829B/zh active Active
- 2008-11-14 WO PCT/CN2008/001878 patent/WO2009100605A1/zh active Application Filing
- 2008-11-14 GB GB1009713.7A patent/GB2469220B/en active Active
- 2008-11-14 CA CA2710862A patent/CA2710862C/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1277027A (zh) * | 1999-06-14 | 2000-12-20 | 中国医学科学院药物研究所 | 蚕沙提取方法、提取物及其用途 |
KR20030079237A (ko) * | 2002-04-02 | 2003-10-10 | 최진호 | 누에 추출물을 이용한 항당뇨환자식의 조성물 |
CN1557824A (zh) * | 2004-02-13 | 2004-12-29 | 南开大学 | 蚕沙总生物碱及其制备方法 |
CN1559539A (zh) * | 2004-02-23 | 2005-01-05 | 南开大学 | 具有α-糖苷酶抑制活性的药物组合物及其用途 |
CN1817350A (zh) * | 2005-12-09 | 2006-08-16 | 南开大学 | 一种蚕沙总生物碱及其制备方法 |
Non-Patent Citations (1)
Title |
---|
WANG X. ET AL.: "Effects of Glycyrrhiza on Rats with Diabetes Mellitus Induced by D- Galactose", CHINA PHARMACEUTICALS, vol. 16, no. 13, 2007, pages 8 - 10 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114594178A (zh) * | 2022-01-25 | 2022-06-07 | 贵州健安德科技有限公司 | 一种利用hplc检测30%氯虫苯甲酰胺悬浮剂中3-甲基吡啶的方法 |
CN114594178B (zh) * | 2022-01-25 | 2024-04-02 | 贵州健安德科技有限公司 | 一种利用hplc检测30%氯虫苯甲酰胺悬浮剂中3-甲基吡啶的方法 |
Also Published As
Publication number | Publication date |
---|---|
GB2469220B (en) | 2012-10-24 |
CA2710862C (en) | 2019-02-26 |
CN101496829A (zh) | 2009-08-05 |
CN101496829B (zh) | 2011-09-14 |
GB2469220A (en) | 2010-10-06 |
GB201009713D0 (en) | 2010-07-21 |
CA2710862A1 (en) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009100605A1 (zh) | 一种治疗消渴病的药物组合物及其制备方法 | |
CN102319245A (zh) | 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 | |
CN111658692A (zh) | 桑提取物在制备治疗哺乳动物中糖脂代谢异常的药物中的用途 | |
Deng et al. | Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats | |
WO2019134159A1 (zh) | 一种白头翁皂苷b4的直肠粘膜给药制剂及其制备方法 | |
CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
CN101474314A (zh) | 儿茶素在制药中的应用 | |
CN104820026A (zh) | 一种荔枝核滴丸质量检测方法 | |
CN102973621B (zh) | 一种三味檀香口服液及其检测方法 | |
Chen et al. | Effects of food on the pharmacokinetic properties and mass balance of henagliflozin in healthy male volunteers | |
CN102153630B (zh) | 一种环八肽及其制备方法和在制药中的应用 | |
CN103432124B (zh) | 氧化苦参碱在制备防治糖尿病肾病药物中的应用 | |
CN104208034A (zh) | 一种格列美脲药物组合物片剂、制备方法及其应用 | |
KR101907179B1 (ko) | 설포라핀을 다량 함유하는 무씨 추출물의 제조방법 및 이로부터 추출된 무씨 추출물을 함유하는 체중, 혈당조절용 및 지방간 예방용 식품 조성물, 약품 조성물, 동물용 의약품 | |
Zhang et al. | Virtual screening, docking, synthesis and bioactivity evaluation of thiazolidinediones as potential PPARγ partial agonists for preparation of antidiabetic agents | |
CN104739813A (zh) | 四氢姜黄素的新用途 | |
Zhang et al. | Study on Optimal Extraction and Hypoglycemic Effect of Quercetin | |
CN103664623A (zh) | 缩酚酸衍生物的用途 | |
CN108619264B (zh) | 一种参黄胶囊及其制备工艺 | |
CN103664568A (zh) | 环草石斛二聚芪类化合物及其制备方法和应用 | |
CN101480455B (zh) | 复方仙鹤草肠炎片及其质量检测方法 | |
CN102631332A (zh) | 一种伏格列波糖片剂及其制备方法 | |
CN101953810B (zh) | 灯盏花素滴丸 | |
TWI843442B (zh) | 包括咖啡萃取物之餐後抗高血糖組成物 | |
CN102657626B (zh) | 一种盐酸吡格列酮药物组合片剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08872357 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 1009713 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20081114 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1009713.7 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2710862 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08872357 Country of ref document: EP Kind code of ref document: A1 |